Using cell-free DNA to diagnose pancreatic cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This research aims to utilize chromatin immunoprecipitation (ChIP) to analyze cell-free DNA for diagnosing and prognosing pancreatic ductal adenocarcinoma (PDAC). By focusing on protein-DNA interactions, the study seeks to identify tumor-specific transcriptional activity in human samples. Given the high mortality rate associated with late-stage PDAC, this approach could provide a non-invasive and cost-effective alternative to traditional screening methods like MRI. The study emphasizes the potential of liquid biopsy techniques to enhance early detection and improve patient outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 18 years old or older
* Pancreatic cancer patients

Exclusion Criteria:

* Children may not register
* Persons who are unable to consent may not register

Where it's running

• University of Central Florida
  Orlando, Florida, United States Recruiting

Study contacts

• Principal investigator: Kersten Schroeder, PhD — University of Central Florida
• Study coordinator: Amoy Fraser, PhD, CCRP, PMP
• Email: amoy.fraser@ucf.edu
• Phone: 4072668742

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Registry of images and videos from endoscopic procedures for pancreatic diseases

  This study is collecting images and videos from endoscopic procedures on patients with pancreatic diseases to help improve how these conditions are understood and treated.

  Recruiting IRCCS San Raffaele · Milan · NCT06344507

• Evaluating Gemcitabine chemotherapy for metastatic pancreatic cancer patients with the GemCore signature

  This study is testing if Gemcitabine chemotherapy can help people with advanced pancreatic cancer who have a specific marker in their tumors.

  Recruiting Institut Paoli-Calmettes · Marseille · NCT06046794

• Evaluating tumor types in pancreatic cancer patients receiving FOLFIRINOX treatment

  This study is testing how different types of pancreatic cancer respond to the chemotherapy FOLFIRINOX before surgery to see if it helps make the tumors easier to remove.

  Recruiting Phase 2 UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT03977233

• Identifying tumor molecules for early pancreatic cancer detection

  This study is trying to find specific molecules in tumors that can help detect pancreatic cancer earlier and more easily for people who might be at risk.

  Recruiting Hull University Teaching Hospitals NHS Trust · Cottingham, Kingston Upon Hull · NCT03536793

• AI-based precision oncology clinical trial matching and registry

  This study is testing whether an AI tool can help match cancer patients with the right clinical trials based on their specific cancer details to see if it improves their chances of getting into trials and their overall outcomes.

  Recruiting at 68 sites Massive Bio, Inc. · Birmingham, Alabama and 67 other locations · NCT03452774

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.